摘要
免疫性血小板减少症(immune thrombocytopenia,ITP)是一种免疫介导的血小板过度破坏或生成不足导致的常见出血性疾病,以血小板减少和出血为主要症状。临床上包括以糖皮质激素、免疫抑制剂的药物治疗及脾脏切除术的外科手术治疗,从而减少血小板的破坏。随着对疾病机制的深入了解,针对巨核细胞增殖分化以增加血小板生成的一类药物血小板生成素受体激动剂(thrombopoietin receptor agonists,TPORAs,TRAs)成为ITP治疗的新途径。本文对TRAs类药物治疗ITP的新药研发现状进行综述。
Immune thrombocytopenia (ITP) is an acquired common hemorrhagic condition characterized by a low platelet count and hemorrhage,which is caused by excessive platelet destruction and thrombopoiesis deficiency.Clinical therapy includes pharmacotherapy with corticosteroids and immunosuppressants and surgical treatment of splenectomy in order to reduce the destruction of platelets.With the deep understanding of the pathogenesis and etiology of ITP,thrombopoietin receptor agonists (TPO-RAs,TRAs) become a new way of ITP treatment,which increases platelet production by stimulating megakaryocytes.In this article,the status of research and development of TRAs for the treatment of ITP is reviewed.
作者
张珂
雷慧
陈曦
赵欣
孙懿
蒲小平
ZHANG Ke LEI Hui CHEN Xi ZHAO Xin SUN Yi PU Xiao-ping(State Key Laboratory of Belting University of Natural and Biomimetic Drugs, Beijing 100191 , China Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Science, Peking University, Beijing 100191 ,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第20期2380-2385,共6页
Chinese Journal of New Drugs
基金
国家重大科学仪器设备开发专项资助项目(2013YQ03065106)
国家自然科学基金资助项目(U1603128)